F-10POS: Oncolytics Biotech Amends Registration Statements
Post-Effective Amendment to Registration Statement
Oncolytics Biotech Inc. has filed a post-effective amendment to multiple registration statements to revise the effectiveness date for the deregistration of unsold securities.
Summary
- Oncolytics Biotech Inc. has filed a Post-Effective Amendment No. 2 to several Form F-10 Registration Statements.
- The primary purpose of this filing is to revise the designated effectiveness date and time for the deregistration of unsold securities.
- The new effectiveness date is set for April 8, 2026, at 4:30 p.m. Eastern time.
- This amendment pertains to the withdrawal of unsold portions of securities previously registered under various statements filed between 2007 and 2024.
- No other changes have been made to the previously filed registration statements.
Sentiment
Score: 3
Explanation: StockSavvy.ai views this filing as having a neutral to slightly negative sentiment due to its administrative nature and focus on deregistering unsold securities, which implies a lack of current or planned offerings.
Future Outlook
The filing does not contain forward-looking statements or guidance; it is solely an administrative amendment to registration statements.
Industry Context
StockSavvy.ai notes that this filing is primarily administrative, related to the management of past registration statements for potential securities offerings. It does not provide new operational or financial information about Oncolytics Biotech's core business activities.
Stakeholder Impact
- Shareholders: No direct impact on current shareholding or company operations. The filing relates to past registration statements.
- Creditors: No direct impact as the filing does not involve new debt or changes to existing obligations.
- Employees: No direct impact on employment or company operations.
Next Steps
- Deregistration of unsold securities from previously filed registration statements.
Key Dates
| Date | Description |
|---|---|
| February 2, 2007 | Initial filing date for Registration Statement on Form F-10 (File No. 333-140460). |
| February 8, 2007 | Initial filing date for Registration Statement on Form F-10 (File No. 333-140529). |
| June 6, 2008 | Initial filing date for Registration Statement on Form F-10 (File No. 333-151513). |
| June 2, 2010 | Initial filing date for Registration Statement on Form F-10 (File No. 333-167250). |
| June 21, 2012 | Initial filing date for Registration Statement on Form F-10 (File No. 333-182260). |
| July 25, 2014 | Initial filing date for Registration Statement on Form F-10 (File No. 333-197633). |
| April 25, 2018 | Initial filing date for Registration Statement on Form F-10 (File No. 333-224432). |
| June 8, 2020 | Initial filing date for Registration Statement on Form F-10 (File No. 333-239025). |
| June 10, 2022 | Initial filing date for Registration Statement on Form F-10 (File No. 333-265510). |
| July 25, 2024 | Initial filing date for Registration Statement on Form F-10 (File No. 333-281009). |
| April 6, 2026 | Date of filing of Post-Effective Amendment No. 2 and signature date. |
| April 8, 2026 | Revised effectiveness date for deregistration of unsold securities. |
Keywords
Oncolytics Biotech, SEC Filing, Registration Statement, Form F-10, Securities Act of 1933, Deregistration, Amendment, Post-Effective Amendment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.